glucocorticoid and mineralocorticoid properties, and each in differing degrees. With the fluoro compound, glycogen deposition activity was twice as great while its sodium-retaining effect was only one-fifth of that of the chloro derivative. Compared with cortisone acetate, 9-alpha-fluoro hydrocortisone acetate was much more potent in glycogenic activity (about 10 times), in producing thymus involution (four times), and in sodium retention.
Data concerning clinical trials with 9-alphafluoro hydrocortisone acetate are meagre. Goldfien and others (1954) found that the substance, administered orally as sole treatment and in extremely low dosage, was highly efficient in maintaining patients with Addison's disease; dosages as small as 0 *25 to 1 mg. a day were sufficient to hold patients in a near optimal state. Metabolic studies conducted by these workers in Addisonian or bilaterally adrenalectomized patients demonstrated that the preparation caused marked retention of sodium and diuresis of potassium, and a striking and prolonged eosinopenic response. Comparative studies in a patient with Addison's disease disclosed that the compound's effect on electrolyte excretion was at least as powerful as that of aldosterone (electrocortin) and was considerably more prolonged. In female patients with adrenogenital syndrome 9-alpha-fluoro hydrocortisone acetate in total daily doses as low as 5 mg. caused marked reduction in urinary 17-ketosteroid excretion.
The immediate results of pilot trials with 9-alphafluoro hydrocortisone acetate in rheumatoid arthritis have recently been described (Boland, 1954; Bayles, 1954; Bunim, 1954) . Incomplete and extremely brief observations made in a total of six patients suggested that the compound exerted a suppressive influence on the disease when taken orally in very small daily amounts, but data were not sufficient to appraise adverse reactions or therapeutic practicability.
Present Investigation
The clinical response to orally administered 9-alpha-fluoro hydrocortisone acetate* was determined in thirteen patients with active peripheral rheumatoid arthritis. The drug was given as initial investigative treatment to seven patients who had received no therapy, other than conservative measures, for at least 3 months beforehand; in three of these medication was later transferred to hydrocortisone (free alcohol) in order to make dosage comparisons. Six patients, who had been maintained on established daily amounts of hydrocortisone (free alcohol) with satisfactory and stable clinical improvement, were transferred directly to the fluoro compound, and differences in dosage requirements for approximately equivalent degrees of rheumatic control were estimated. hydrocortisone (free alcohol) per day, was transferred to 9-alpha-fluoro hydrocortisone acetate in doses of 5 mg. a day, and 4 days later experienced a severe articular relapse. Dosage comparisons were not permitted in this case because marked fluid retention and moderate hypertension also developed and these prohibited trials with larger doses of the fluoro compound. From comparisons made in the remaining eight patients, the calculated dosage ratios of hydrocortisone (free alcohol) to 9-alpha-fluoro hydrocortisone acetate ranged from 83: 1 to 12 5: 1. Thus it appeared from clinical appraisals alone that the milligram anti-rheumatic potency of 9-alpha-fluoro hydrocortisone acetate was roughly ten times greater than that of hydrocortisone (free alcohol).
Adverse Reactions During the short periods of observation embraced by this study, and with the dosage range explored, two adverse reactions to 9-alpha-fluoro hydrocortisone acetate were prominent: fluid retention and blood pressure elevation. In each instance where the patient was transferred to hydrocortisone (free alcohol) in larger but equally efficient amounts, signs of fluid retention disappeared quite promptly, ordinarily within 2 to 5 days. These observations suggested that the substitution of a fluorine atom at the ninth carbon position of hydrocortisone enhanced not only the anti-inflammatory activity of the steroid but also its salt and water retaining property to an even greater degree. Blood pressure elevations were recorded in six of the thirteen patients; these were regarded as slight in three and moderate in three. In each instance where transfer to hydrocortisone (free alcohol) was made the blood pressure returned to its former level within 4 to 14 days.
The treatment periods with 9-alpha-fluoro hydrocortisone acetate were too brief to permit assessment of other possible endocrine side-effects. One patient (Case 2), who received the preparation in maintenance dosages of 4 mg. a day for a total of 77 days, exhibited slight, questionable, facial mooning after 4 weeks of administration.
Two unusual reactions were observed. One patient (Case 12) suddenly experienced dryness of the mouth, a "toxic" feeling, and low-grade fever after the fluoro compound had been taken for 14 days; the symptoms disappeared 2 days after resumption of hydrocortisone (free alcohol) therapy. Another patient (Case 13) developed abdominal bloating, moderate facial oedema, and Grade II albuminuria with cylindruria but without azotaemia after 13 days of medication; the manifestations were corrected within 5 days of transfer to hydrocortisone (free alcohol). Two other patients complained of intermittent nausea.
Comment
The number of cases studied were too few and the periods of observation too short to allow more than limited and provisional deductions. However, it was obvious to us that the powerful salt and water retaining properties of 9-alpha-fluoro hydrocortisone, and perhaps other metabolic effects which may ensue with prolonged administration, would probably prohibit its employment as systemic medication for rheumatoid arthritis. Dosages Pronounced articular relapse 4 days after transfer to 9-alpha-fluoro hydrocortisone acetate. Fluid retention and blood pressure elevation disallowed trial of larger doses retention which in some were pronounced and intolerable. The fact that this complication disappeared promptly when treatment was changed to hydrocortisone (free alcohol) in larger but equally efficient doses signified that the substitution of a fluorine atom at the ninth carbon position of hydrocortisone enhances its salt-retaining effect more than its anti-phlogistic action. These observations are of interest chiefly because they demonstrate that it is possible to enhance the anti-inflammatory activity of hydrocortisone, as well as to modify other of its properties, by altering its chemical structure. This implies that it is not beyond the realm of hope that, through other substitutions or changes in chemical configuration, a derivative of hydrocortisone may be prepared which, in effective anti-rheumatic doses, may be devoid of significant complications. Summary A halogenated derivative of hydrocortisone-9-alpha-fluoro hydrocortisone acetate was administered as investigative therapy to thirteen patients with active rheumatoid arthritis. Seven patients received the preparation as initial medication; three were transferred later to hydrocortisone (free alcohol) for comparison of dosage requirements.
Six patients who were being maintained on established daily amounts of hydrocortisone (free alcohol) were transferred directly to the fluoro compound and the doses needed for similar degrees of rheumatic control were compared.
The following conclusions were drawn: (1) Weight for weight, the anti-rheumatic potency of 9-alpha-fluoro hydrocortisone acetate was found to be much greater than that of the parent compound, hydrocortisone. This was indicated by the following:
(a) Initial suppressive doses of the fluoro derivative ranging from 3 to 8 mg. a day were sufficient, in five of seven patients, to promote rapid improvement in the rheumatic manifestations; (b) Comparisons of maintenance dosage requirements for approximately equivalent degrees of clinical control revealed that, in eight of nine patients, the anti-rheumatic power of 9-alphafluoro hydrocortisone acetate, milligram for milligram, was roughly ten times that of hydrocortisone (free alcohol). (2) With the small total daily amounts of the fluoro compound employed, fluid retention developed in twelve of the thirteen patients, and became pronounced in some. This suggested that the substitution of a fluorine atom at the ninth carbon position increased the electrolytic activity of hydrocortisone more than it enhanced its anti-phlogistic property. The excessive salt and water retaining effect of the fluoro derivative would seem to preclude its use as practical systemic therapy in rheumatoid arthritis.
(3) These observations demonstrate that the antiinflammatory potency of hydrocortisone may be enhanced, and other of its properties modified, by altering its formula. This raises a hope that, through changes in structure or other chemical substitutions, a more successful therapeutic agent for rheumatoid arthritis may be produced in the future. (3) Ces observations montrent qu'en changeant la formule on peut augmenter le pouvoir anti-inflammatoire de la cortisone et modifier ses autres proprietes. Cela permet d'esperer qu'on creera un jour un agent therapeutique plus efficace contre l'arthrite rhumatismale par un changement de la structure ou par une autre substitution chimique.
Ensayos clinicos preliminares del acetato de 9-alfa-fluoro hidrocortisona en la artritis reumatoide SUMARIO Un derivado hal6geno de hidrocortisona-acetato de 9-alfa-fluoro hidrocortisona-fue administrado, como terapia investigadora, a trece enfermos con artritis reumatoide activa. Siete enfermos recibieron esta preparaci6n como medicaci6n inicial; tres de ellos fueron luego trasladados a hidrocortisona (alcohol libre) para comparar las dosis requeridas. Seis enfermos tratados anteriormente con dosis diarias fijas de hidrocortisona (alcohol libre) fueron sometidos directamente al tratamiento con el compuesto de fluor, comparindose las dosis requeridas para el grado similar de control del reumatismo.
Se concluy6 lo siguiente:
(1) A peso igual, el poder antirreumatico del acetato de 9-alfa-fluoro hidrocortisona fue mucho mayor que el del compuesto pariente, la hidrocortisona, lo que fue indicado por lo siguiente:
(a) Dosis iniciales supresoras de 3 a 8 mg. por dia del derivado de fluor fueron suficientes, en cinco de los siete enfermos, para motivar una mejoria rapida de las manifestaciones reumaticas.
(b) Al comparar las dosis requeridas para mantener un control clinico de grado aproximadamente equivalent, se hall que la potencia antirreumitica del acetato de 9-alfa-fluoro hidrocortisona, miligramo por miligramo, fue cerca de diez veces mayor que la de la hidrocortisona (alcohol libre).
(2) A pesar de la pequefiez de las dosis diarias totales del compuesto de fluor, sobre trece enfermos doce acusaron una retenci6n hidrica que en algunos lleg6 a ser pronunciada. Esto sugiere que la sustituci6n de un Atomo de fluor en la novena posici6n del carbon aumenta mas la acci6n electrolitica que la antiflogistica de la hidrocortisona. Esta acci6n retentive de sal y de aqua en exceso impediria la aplicaci6n prictica del compuesto de fluor en la artritis reumitica.
(3) Estas observaciones muestran que cambiando la formula se puede aumentar el poder anti-inflamatorio y modificar otras propiedades de la cortisone. Esto permite esperar que se llegard a producir por un cambio de la estructura o por otra sustituci6n quimica un mejor agente terapeutico contra la artritis reumatoide,
